Ziopharm Oncology Inc (ZIOP.O) said its experimental cancer treatment, Zymafos, met a key goal in a mid-stage trial, driving its shares up as much as 38 percent.
You do not have JavaScript enabled or are using an older version of Adobe Flash. You can update your version of Adobe Flash here.
Stay updated on the latest technologies and news with Biocompare's newsletters (See samples here)